US 11293009
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
granted A61KA61K31/661A61K35/17
Quick answer
US patent 11293009 (Remnant tumor infiltrating lymphocytes and methods of preparing and using the same) held by Iovance Biotherapeutics, Inc. expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/661, A61K35/17, A61K38/2013, A61K40/11